» Articles » PMID: 11746512

Cloning and Characterization of Osteoactivin, a Novel CDNA Expressed in Osteoblasts

Overview
Journal J Cell Biochem
Date 2001 Dec 18
PMID 11746512
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoblast development is a complex process involving the expression of specific growth factors and regulatory proteins that control cell proliferation, differentiation, and maturation. In this study, we used the rat mutation, osteopetrosis (op), to examine differences in skeletal gene expression between mutant op and normal littermates. Total RNA isolated from long bone and calvaria was used as a template for mRNA differential display. One of many cDNAs that were selectively expressed in either normal or mutant bone was cloned and sequenced and found to share some homology to the human nmb and Pmel 17 genes. This novel cDNA was named osteoactivin. Osteoactivin has an open reading frame of 1716 bp that encodes a protein of 572 amino acids with a predicted molecular weight of 63.8 kD. Protein sequence analysis revealed the presence of a signal peptide and a cleavage site at position 23. The protein also has thirteen predicted N-linked glycosylation sites and a potential RGD integrin recognition site at position 556. Northern blot analysis confirmed that osteoactivin was 3- to 4-fold overexpressed in op versus normal bone. RT-PCR analysis showed that osteoactivin is most highly expressed in bone compared with any of the other non-osseous tissues examined. In situ hybridization analysis of osteoactivin in normal bone revealed that it is primarily expressed in osteoblasts actively engaged in bone matrix production and mineralization. In primary rat osteoblast cultures, osteoactivin showed a temporal pattern of expression being expressed at highest levels during the later stages of matrix maturation and mineralization and correlated with the expression of alkaline phosphatase and osteocalcin. Our findings show that osteoactivin expression in bone is osteoblast-specific and suggest that it may play an important role in osteoblast differentiation and matrix mineralization. Furthermore, osteoactivin overexpression in op mutant bone may be secondary to the uncoupling of bone resorption and formation resulting in abnormalities in osteoblast gene expression and function.

Citing Articles

Biofluid GPNMB/osteoactivin as a potential biomarker of ageing: A cross-sectional study.

Liu Y, Pang J, Zhang C, Zeng L, Wang Y, Wang S Heliyon. 2024; 10(17):e36574.

PMID: 39263169 PMC: 11388787. DOI: 10.1016/j.heliyon.2024.e36574.


Glycoprotein non-metastatic melanoma protein B expression correlates with the prognosis of acute liver injury/failure.

Kumagai K, Kanmura S, Mawatari S, Nakamura Y, Eguchi H, Taniyama O Front Cell Dev Biol. 2023; 11:1242152.

PMID: 37941897 PMC: 10627855. DOI: 10.3389/fcell.2023.1242152.


Glycoprotein nonmetastatic melanoma protein B (GNMPB) as a novel biomarker for cerebral adrenoleukodystrophy.

Taghizadeh L, King C, Nascene D, Gupta A, Orchard P, Higgins L Sci Rep. 2022; 12(1):7985.

PMID: 35568699 PMC: 9107455. DOI: 10.1038/s41598-022-11552-7.


Glycoprotein nonmetastatic melanoma protein B regulates lysosomal integrity and lifespan of senescent cells.

Suda M, Shimizu I, Katsuumi G, Hsiao C, Yoshida Y, Matsumoto N Sci Rep. 2022; 12(1):6522.

PMID: 35444208 PMC: 9021310. DOI: 10.1038/s41598-022-10522-3.


Association Between Factors Involved in Bone Remodeling (Osteoactivin and OPG) With Plasma Levels of Irisin and Meteorin-Like Protein in People With T2D and Obesity.

Cherian P, Al-Khairi I, Jamal M, Al-Sabah S, Ali H, Dsouza C Front Endocrinol (Lausanne). 2021; 12:752892.

PMID: 34777249 PMC: 8588843. DOI: 10.3389/fendo.2021.752892.